Intérêt du dosage des biomarqueurs du LCR dans les démences dégénératives

With the emergence of disease modifier therapies, it is crucial to improve an early and accurate diagnosis for degenerative dementia. For many years, measurement of biomarkers in cerebrospinal fluid (CSF) is used in clinical practice for the diagnosis of Alzheimer's disease (AD). Full profile for the AD diagnosis is a significant variation in biomarker concentrations compared to control subjects, with higher doses of T-tau and P-tau and a decrease of Aβ1-42. CSF biomarkers reflect the presence of pathological lesions of AD. They enable a reliable and early diagnosis of the disease, with a sensitivity and specificity above 80%, values that increase when combined with clinical and imaging markers. For non-Alzheimer degenerative dementia, CSF biomarkers are not as good as for the diagnosis of AD. Currently, it is necessary to test and develop other markers of CSF and plasma markers.